Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, First-in-human, Open-label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral CDK2 Degrader NKT3964 in Adults With Advanced/Metastatic Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06586957
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:29:07.215357+00:00
Published At
2026-04-21T00:00:00+00:00
Record Updated At
2026-04-21
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Solid Tumor", "Advanced Solid Tumor", "Solid Tumor, Adult", "Metastatic Tumor", "Ovarian Cancer", "Ovarian Neoplasms", "Ovarian Carcinoma", "Metastatic Ovarian Carcinoma", "Endometrial Neoplasms", "Endometrial Diseases", "Metastatic Endometrial Cancer", "Triple Negative Breast Cancer", "Metastatic Endometrial Carcinoma", "Advanced Endometrial Carcinoma", "Advanced Ovarian Carcinoma", "Gastric Cancer", "Advanced Gastric Carcinoma", "Metastatic Gastric Cancer", "Metastatic Gastric Carcinoma", "Small Cell Lung Cancer", "Small Cell Lung Carcinoma", "Triple Negative Breast Neoplasms", "Platinum-resistant Ovarian Cancer", "Platinum-refractory Ovarian Carcinoma", "CCNE1 Amplification", "Hormone Receptor Negative Breast Carcinoma", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "Progesterone-receptor-positive Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-21"
protocolSection.identificationModule.nctId
"NCT06586957"
protocolSection.identificationModule.officialTitle
"A Phase 1, First-in-human, Open-label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral CDK2 Degrader NKT3964 in Adults With Advanced/Metastatic Solid Tumors"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Solid Tumor (protocolSection.conditionsModule.conditions)
  • Advanced Solid Tumor (protocolSection.conditionsModule.conditions)
  • Solid Tumor, Adult (protocolSection.conditionsModule.conditions)
  • Metastatic Tumor (protocolSection.conditionsModule.conditions)
  • Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Ovarian Neoplasms (protocolSection.conditionsModule.conditions)
  • Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Neoplasms (protocolSection.conditionsModule.conditions)
  • Endometrial Diseases (protocolSection.conditionsModule.conditions)
  • Metastatic Endometrial Cancer (protocolSection.conditionsModule.conditions)
  • Triple Negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Endometrial Carcinoma (protocolSection.conditionsModule.conditions)
  • Advanced Endometrial Carcinoma (protocolSection.conditionsModule.conditions)
  • Advanced Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Advanced Gastric Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Gastric Carcinoma (protocolSection.conditionsModule.conditions)
  • Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Small Cell Lung Carcinoma (protocolSection.conditionsModule.conditions)
  • Triple Negative Breast Neoplasms (protocolSection.conditionsModule.conditions)
  • Platinum-resistant Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Platinum-refractory Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • CCNE1 Amplification (protocolSection.conditionsModule.conditions)
  • Hormone Receptor Negative Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast (protocolSection.conditionsModule.conditions)
  • Progesterone-receptor-positive Breast Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.